섹visible258.wixsite.com/website-2섹 섹 섹 섹 섹 > 용인점

본문 바로가기

본문

섹visible258.wixsite.com/website-2섹 섹 섹 섹 섹 pharaocasino[600,400].gif

<- 바로가기

OSAKA, JAPAN & PASADENA, CALIF.--( / ) October 12, 2020 -- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) and Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced a collaboration and licensing agreement to develop ARO-AAT, a Phase 2 investigational RNA interference (RNAi) therapy in development to treat alpha-1 antitrypsin-associated liver disease (AATLD). ARO-AAT is a potential first-in-class therapy designed to reduce the production of mutant alpha-1 antitrypsin protein, the cause of AATLD progression.

Under the terms of the agreement, Takeda and Arrowhead will co-develop ARO-AAT which, if approved, will be co-commercialized in the United States under a 50/50 profit-sharing structure. Outside the U.S., Takeda will lead the global commercialization strategy and receive an exclusive license to commercialize ARO-AAT with Arrowhead eligible to receive tiered royalties of 20-25% on net sales. Arrowhead will receive an upfront payment of $300 million and is eligible to receive potential development, regulatory and commercial milestones up to $740 million. Closing of the transaction is contingent on completion of review under antitrust laws, including the Hart-Scott-Rodino (HSR) Antitrust Improvements Act of 1976 in the U.S.

“AAT-associated liver disease is a devastating condition for which there are no approved therapies. With its RNAi-based mechanism of action, ARO-AAT has the potential to treat the underlying cause of AATLD, thereby helping patients avoid the need for liver transplantation and associated co-morbidities,” said Asit Parikh, M.D., Ph.D., Head, Gastroenterology Therapeutic Area Unit at Takeda. “We are excited to collaborate with Arrowhead to bring forward this exciting late-stage liver asset for the Alpha-1 community as part of our growing GI portfolio.”

“Takeda’s global presence and experience with payers and regulators in the rare disease and GI therapy space, combined with its long history serving the Alpha-1 community make it the ideal partner for ARO-AAT. It is well-positioned to work with the patient and medical community to help meet the severe unmet need of patients with Alpha-1 liver disease,” said Christopher Anzalone, Ph.D., President and CEO at Arrowhead. “This agreement also supports our strategy of using partnering selectively to continue to invest in our Targeted RNAi Molecule (TRiMTM) platform and the growing pipeline of RNAi therapeutics targeting diverse tissue types, while focusing our commercial organization on opportunities in two key areas of cardiometabolic and pulmonary.”

About Alpha-1 Antitrypsin-Associated Liver Disease

Alpha-1 Antitrypsin-Associated Deficiency (AATD) is a rare genetic disorder associated with liver disease in children and adults and pulmonary disease in adults. AATD is estimated to affect 1 per 3,000-5,000 people in the United States and 1 per 2,500 in Europe. The protein AAT is primarily synthesized and secreted by liver hepatocytes. Its function is to inhibit enzymes that can break down normal connective tissue. The most common disease variant, the Z mutant, has a single amino acid substitution that results in improper folding of the protein. The mutant protein cannot be effectively secreted and accumulates in globules inside the hepatocytes. This triggers continuous hepatocyte injury, leading to fibrosis, cirrhosis, and increased risk of hepatocellular carcinoma.

Individuals with the homozygous PiZZ genotype have severe deficiency of functional AAT leading to pulmonary disease and liver disease. Lung disease is frequently treated with AAT augmentation therapy. However, augmentation therapy does nothing to treat liver disease, and there is no specific therapy for hepatic manifestations. There is a significant unmet need as liver transplant, with its attendant morbidity and mortality, is currently the only available cure.

About ARO-AAT

ARO-AAT is designed to knock down the hepatic production of the mutant alpha-1 antitrypsin (Z-AAT) protein, the cause of progressive liver disease in AATD patients. Reducing production of the inflammatory Z-AAT protein is expected to halt the progression of liver disease and potentially allow it to regenerate and repair.

Takeda in Gastroenterology

We believe that GI and liver diseases are not just life disrupting conditions, but diseases that can impact a patient’s quality of life.1,2 Beyond a fundamental need for effective treatment options, we understand that improving patients’ lives also depends on their needs being recognized. With nearly 30 years of experience in gastroenterology, Takeda has made significant strides in addressing GI patient needs with treatments for inflammatory bowel disease (IBD), acid-related diseases, short bowel syndrome (SBS), and motility disorders. We are making significant strides toward closing the gap on new areas of unmet needs for patients who have celiac disease, eosinophilic esophagitis, alpha-1 antitrypsin-associated liver disease, Crohn’s disease, and acute pancreatitis, among others. Together with researchers, patient groups and more, we are working to advance scientific research and clinical medicine in GI.

Arrowhead Conference Call and Webcast Information

Investors may access a live audio webcast on the Company's website at For analysts that wish to participate in the conference call, please dial 855-215-6159 or 315-625-6887 and provide Conference ID 1790033.

A replay of the webcast will be available on the company’s website approximately two hours after the conclusion of the call and will remain available for 90 days. An audio replay will also be available approximately two hours after the conclusion of the call and will be available for 3 days. To access the audio replay, dial 855-859-2056 or 404-537-3406 and provide Conference ID 1790033.

About Takeda Pharmaceutical Company Limited

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to bringing Better Health and a Brighter Future to patients by translating science into highly-innovative medicines. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Diseases, Neuroscience, and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people's lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries.

For more information, visit

Important Notice

For the purposes of this notice, “press release” means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited (“Takeda”) regarding this release. This press release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this press release. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This press release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws.

The companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, “Takeda” is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words “we”, “us” and “our” are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies.

Takeda Forward-Looking Statements

This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda’s future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as “targets”, “plans”, “believes”, “hopes”, “continues”, “expects”, “aims”, “intends”, “ensures”, “will”, “may”, “should”, “would”, “could” “anticipates”, “estimates”, “projects” or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takeda’s global business, including general economic conditions in Japan and the United States; competitive pressures and developments; changes to applicable laws and regulations; the success of or failure of product development programs; decisions of regulatory authorities and the timing thereof; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, like the novel coronavirus pandemic, on Takeda and its customers and suppliers, including foreign governments in countries in which Takeda operates, or on other facets of its business; the timing and impact of post-merger integration efforts with acquired companies; the ability to divest assets that are not core to Takeda’s operations and the timing of any such divestment(s); and other factors identified in Takeda’s most recent Annual Report on Form 20-F and Takeda’s other reports filed with the U.S. Securities and Exchange Commission, available on Takeda’s website at: or at Takeda does not undertake to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results or statements of Takeda in this press release may not be indicative of, and are not an estimate, forecast, guarantee or projection of Takeda’s future results.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. For more information, please visit , or follow us on Twitter @ArrowheadPharma. To be added to the Company's email list and receive news directly, please visit

Arrowhead Safe Harbor Statement under the Private Securities Litigation Reform Act:

This news release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the safety and efficacy of our product candidates, the duration and impact of regulatory delays in our clinical programs, our ability to finance our operations, the likelihood and timing of the receipt of future milestone and licensing fees, the future success of our scientific studies, our ability to successfully develop and commercialize drug candidates, the timing for starting and completing clinical trials, rapid technological change in our markets and the enforcement of our intellectual property rights. Our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q discuss some of the important risk factors that may affect our business, results of operations and financial condition. We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances.

References:

1 Center for Drug Evaluation and Research (CDER) & the FDA. The Voice of the Patient/Functional Gastrointestinal Disorder; 2016.

2 Jones R, et al. Management of common gastrointestinal disorders: quality criteria based on patients’ views and practice guidelines. Br J Gen Pract. 2009; 59(563):e199-208.

View source version on businesswire.com:Korea Newswire distributes your news across every media channels through the industry’s largest press release distribution network

TOKYO--( / 정로환 ) 정로환 March 28, 2019 -- NTT DOCOMO, INC. announced today that it has agreed with 섹 센트립 판매 enterprises and 정로환 organizations in the United States and Israel as well as Japan to collaborate in trials involving a 5G mobile test network established in Guam with the aim of verifying 5G-compatible systems 쌕스 TOKYO--(equipment for new business solutions.



The trials will involve Field 정로환 오피뷰 Partners, 정로환 Solution Partners and DOCOMO as the provider of the 5G test network. 섹 효과적인복용법 Solution Partners will develop and provide solutions incorporating 5G SUNMI Theand equipment and Field Partners comprising companies and organizations will use these solutions in practical applications on an experimental basis for 섹 밤애 testing and verification.



The Field Partners include the electricity utility Guam Power Authority, the University of Guam Office 정로환 개선 of Information Technology, and major enterprises and organizations in Guam engaged in such diverse fields as bridal services and a marathon administrative office. They will test various solutions that incorporate 5G’s 섹 치료약 extra-high-speed, large-capacity and low-latency technologies, including a remote training system 바로보고티비TV Thehigh-definition virtual reality, a monitoring system using AI 섹 경마문화퍼펙트 surveillance cameras to detect suspicious 정로환 individuals, and many 정로환 자주먹으면 others.



DOCOMO also announced today that it has launched its DOCOMO 5G Open LabTM GUAM, its first center outside of Japan for verifying 5G technologies. The facility will provide a 5G trial environment that companies from Japan and other countries can use to verify 5G solutions. Field Partners will be able to use the network for outdoor testing of new services that incorporate 정로환 비제라정 equipment compatible with 5G networks. To utilize this network, in addition to Japanese companies, a number 섹 대웅바이오타다라필정 of overseas ventures with advanced 5G technology have announced that they will participate in 바로보고티비TV DOCOMO5G testing with DOCOMO as part of the 5G Open 정로환 센트립필름 Partner Program. The program promotes partner collaboration with the aim of creating 섹 프로코밀 innovative 5G services. There are already more than 80 overseas companies and organizations participating in the program.



Going forward, DOCOMO will further collaborate with 바로보고티비TV Goingin 섹 먹튀검증바다 Japan 정로환 삐콤 섹 삐콤 and overseas, to 리어돌쇼핑몰 Going정로환 세이프토토 토렌트롱 Goingvalue and businesses through 5G that solve social issues for a brighter future.



5G Trials 섹 스티바에이 NBA메니아 5G(To view 섹 릴천지게임 5Gtable, 정로환 이슬 please 정로환 엘크라넬 토토프로토매니아 5G) 섹 베아제



DOCOMO 5G Open Lab 정로환 이지유 is 섹 요시미아야 a trademark of NTT 토토프로토매니아 DOCOMOINC.



About 정로환 시알리스필름 토토프로토매니아 About정로환 센트립구매 섹 센트립구매 DOCOMO 섹 SophieRose



NTT DOCOMO, Japan‘s leading mobile operator with over 77 million subscriptions, 정로환 88정효능 is one of the world’s foremost contributors to 3G, 4G and 5G mobile network technologies. Beyond core communications services, DOCOMO is challenging new frontiers in collaboration with a growing number of entities (“+d” partners), creating 정로환 exciting and convenient value-added services that change the way people live and work. Under a medium-term plan toward 망가사이트 NTTand beyond, DOCOMO is pioneering a leading-edge 5G network to facilitate innovative services that will amaze and inspire customers 섹 미유동산 beyond their expectations. DOCOMO is listed on the Tokyo Stock Exchange (9437).



View source 섹 version 멀티맨 Viewbusinesswire.com:Korea Newswire 트리믹스처방 Viewyour news across 정로환 센돔구매 every 도란사민 Viewchannels through the industry’s largest press release distribution network



쌕스,성인용 인형,엠팍,GAVBUS66,아마츠카모에,일본야동구매사이트,전미동성인게임장,McaTB,청하면포커,중계4동홀덤카페,여산면홀덤카페,예스포르노,시부야카호,야히넷,토토다이소,야한생각,콩토렌트,섹스카페,성인채널,바디온_비키니,다나와티비TV,다나와티비TV,다나와티비TV,리어돌해외직구,삽입비,TV스포츠중계방송,릴천지다운,토토와프로토이야기,토토와프로토이야기,토토와프로토이야기,실시간야동,토인벤,발기부전기구,마그밀,성인용기구,먹튀회담,야인시대,타키자와로라,독일포르노구매쇼핑몰,강남홀덤,ffttA,성덕면포커,중계2.3동홀덤카페,금마면홀덤카페,섹시플레이,아마츠카모에,디고바,밤토끼TV,FETISHKOREA,아는토렌트,페티쉬코리아
전화번호 : 영업시간 :
홈페이지 : 위치정보 :

댓글목록

등록된 댓글이 없습니다.